ImmuCell Corporation (ICCC) |
6.8 0.08 (1.19%) 10-10 16:00 |
Open: | 6.82 |
High: | 6.99 |
Low: | 6.76 |
Volume: | 26,527 |
Market Cap: | 62(M) |
PE Ratio: | 32.38 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 8.16 |
Resistance 1: | 6.99 |
Pivot price: | 6.36 |
Support 1: | 6.12 |
Support 2: | 5.59 |
52w High: | 7.6 |
52w Low: | 3.38 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
EPS | 0.210 |
Book Value | 3.300 |
PEG Ratio | 0.00 |
Gross Profit | 1.214 |
Profit Margin (%) | 6.23 |
Operating Margin (%) | 8.84 |
Return on Assets (ttm) | 3.0 |
Return on Equity (ttm) | 6.6 |
Thu, 09 Oct 2025
ImmuCell appoints Olivier te Boekhorst as CEO - MSN
Thu, 09 Oct 2025
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne - Zacks Investment Research
Thu, 09 Oct 2025
ImmuCell's (ICCC) "Hold (C-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Tue, 07 Oct 2025
ImmuCell Corporation Reports Preliminary Third Quarter 2025 Sales Results - Quiver Quantitative
Wed, 01 Oct 2025
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average - Should You Sell? - MarketBeat
Tue, 30 Sep 2025
Immucell Appoints New CEO Olivier te Boekhorst - TipRanks
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |